NASDAQ:CCCC C4 Therapeutics Q3 2024 Earnings Report $3.08 -0.23 (-6.95%) Closing price 04:00 PM EasternExtended Trading$3.07 -0.01 (-0.26%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast C4 Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.40Beat/MissBeat by +$0.05One Year Ago EPSN/AC4 Therapeutics Revenue ResultsActual Revenue$15.36 millionExpected Revenue$5.95 millionBeat/MissBeat by +$9.41 millionYoY Revenue GrowthN/AC4 Therapeutics Announcement DetailsQuarterQ3 2024Date10/31/2024TimeBefore Market OpensConference Call DateThursday, October 31, 2024Conference Call Time7:00AM ETUpcoming EarningsC4 Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) C4 Therapeutics Earnings HeadlinesC4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide ReadoutsSeptember 5, 2026 | seekingalpha.comC4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple ...September 3, 2026 | markets.businessinsider.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 23 at 1:00 AM | The Oxford Club (Ad)C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual MeetingSeptember 3, 2026 | globenewswire.comC4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 11, 2026 | finance.yahoo.comC4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?July 3, 2026 | insidermonkey.comSee More C4 Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like C4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on C4 Therapeutics and other key companies, straight to your email. Email Address About C4 TherapeuticsC4 Therapeutics (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses targeted protein degradation, an approach designed to recruit the body’s natural protein-disposal system to remove specific proteins rather than simply inhibit their activity. C4 Therapeutics develops its drug candidates through its proprietary TORPEDO platform, which is intended to identify and optimize small-molecule degraders for challenging biological targets. Its research and development programs have included investigational therapies for cancer, including candidates designed to target proteins involved in tumor growth and survival, such as KRAS G12C and BRD9. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics conducts research and clinical-development activities primarily in the United States. The company has also pursued strategic collaborations with larger pharmaceutical companies to advance targeted protein-degradation research and potential therapies.View C4 Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
